Search Results
May 11, 2026, 08:30 ET Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson's Cell Therapy
advancement of the program. Dr. Mendonça is a board-certified neurologist who has held senior clinical development roles at Bial, AbbVie and Novartis Gene Therapies, spanning early- and late-stage programs in neuroscience and rare diseases across North America and Europe."This cell
More news about: Cellular Intelligence
May 11, 2026, 08:30 ET Cellular Intelligence, an AI-native TechBio, Enters Agreement with Novo Nordisk to Advance Clinical-Stage Parkinson's Cell Therapy
advancement of the program. Dr. Mendonça is a board-certified neurologist who has held senior clinical development roles at Bial, AbbVie and Novartis Gene Therapies, spanning early- and late-stage programs in neuroscience and rare diseases across North America and Europe."This cell
More news about: Cellular Intelligence
May 11, 2026, 08:30 ET Cellular Intelligence, et AI-baseret TechBio-selskab, indgår aftale med Novo Nordisk om at fremme celleterapi mod Parkinsons sygdom i klinisk fase
programmet. Dr. Mendonça er en speciallæge i neurologi, der har beklædt ledende stillinger inden for klinisk udvikling hos Bial, AbbVie og Novartis Gene Therapies, hvor han har arbejdet med programmer i både tidlige og sene faser inden for neurovidenskab og sjældne sygdomme i både Nordamerika og Europa.
More news about: Cellular Intelligence
May 11, 2026, 08:14 ET Myrtelle to Present Clinical Data and Regulatory Progress for MYR-101 Gene Therapy Program at ASGCT 2026
"Beyond neurons: Glial-targeted gene and cell therapies for neurologic and ophthalmic diseases," organized by the Neurologic and Ophthalmic Cell and Gene Therapy Committee, on Tuesday, May 12th, from 3:30 p.m. to 5:00 p.m. ET. Her presentation, "AAV Mediated Gene Therapy for Canavan Disease
More news about: Myrtelle, Inc
May 11, 2026, 08:05 ET Ecovyst Announces Term Loan Amendment and Increase
result of new information, future developments or otherwise, except as may be required by applicable law.For more information:Gene Shiels – Director of Investor Relations(484) 617 [email protected]
More news about: Ecovyst Inc.
May 11, 2026, 08:00 ET HydroGene to present non-viral DNA delivery in non-human primates demonstrating expression and durability comparable to commercial AAV products at ASGCT 2026
company demonstrates the significant advances in gene delivery into the liver non-human primates (NHP) as well as large animal models of genetic disease. HydroGene believes the achievements represent a significant advance for the field of non-viral gene therapy, which previously suffered significant toxicities,
More news about: HydroGene Therapeutics
May 11, 2026, 08:00 ET Benchling Biologics delivers no-code antibody format design and automated registration at scale
weeks of waiting to days.During registration, Benchling automatically characterizes and validates each entity, including CDR/FR regions, germline gene identification, liability detection, and format-aware validation. The system registers DNA sequences, amino acid sequences, chains, and domains as reusable
More news about: Benchling
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
HOPEWELL, N.J., May. 11, 2026 /PRNewswire/ -- Given the accelerating global momentum in CAR-T and gene therapies, ProBio Inc. and Curocell have achieved a significant milestone with the BLA regulatory approval and commercial readiness of
More news about: ProBio Inc.
May 11, 2026, 07:00 ET Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting
patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced multiple presentations at the 29th annual meeting of the American Society of Gene and Cell Therapy (
More news about: Nanoscope Therapeutics
May 11, 2026, 06:00 ET Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
(21%).NRG1 Gene Fusion Positive Advanced, Unresectable or Metastatic CholangiocarcinomaSerious adverse reactions occurred in 23% of patients with NRG1 gene fusion positive cholangiocarcinoma who received BIZENGRI (n=22).In patients with NRG1 gene fusion positive
More news about: Partner Therapeutics, Inc.
May 08, 2026, 20:30 ET China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients
NUT carcinoma is a rare, poorly differentiated carcinoma characterized by NUTM1 gene rearrangement. The disease progresses rapidly, with a median survival of only approximately 6.5 months. It commonly occurs in the lungs, head, and neck
More news about: Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
May 08, 2026, 20:30 ET China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients
NUT carcinoma is a rare, poorly differentiated carcinoma characterized by NUTM1 gene rearrangement. The disease progresses rapidly, with a median survival of only approximately 6.5 months. It commonly occurs in the lungs, head, and neck
More news about: Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
May 08, 2026, 10:16 ET Compound Found in Aged Garlic Extract Shows Potential to Improve Muscle Health During Aging
form a complex with two essential proteins, STRAD and MO25. This complex formation stimulates the anti-aging protein SIRT1 (known as the longevity gene) which subsequently triggers the release of extracellular vesicles containing the key enzyme eNAMPT into the bloodstream.In a surprising discovery,
More news about: Wakunaga of America
May 08, 2026, 08:30 ET Day One and Servier Complete Enrollment in Pivotal Phase 3 FIREFLY-2 Trial of Tovorafenib as a Front-Line Treatment for Pediatric Low-Grade Glioma (pLGG)
children per year who are eligible for front-line systemic therapy.i, ii BRAF is the gene most commonly altered in pLGG, which includes two primary types of BRAF alterations – a BRAF gene fusion and BRAF point mutation. These BRAF alterations account for >50% of pLGG cases worldwide
More news about: Servier Pharmaceuticals
May 08, 2026, 08:17 ET AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest
AAVone®2.1 is designed to support the clinical and commercial scalability of AAV-based gene therapy programs. "AAV manufacturing remains one of the most important technical and economic challenges in gene therapy," said Qizhao Wang, Ph.D., Chief Technology Officer of AAVnerGene. "Conventional
More news about: AAVnerGene Inc.
May 08, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific Conferences
American Society of Gene and Cell Therapy Annual Meeting (Boston)Poster Presentation: Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cellsDate:
More news about: INOVIO Pharmaceuticals, Inc.
May 08, 2026, 07:57 ET AAVnerGene Announces AAVone®2.1, a Next-Generation Single-Plasmid AAV Production Platform Achieving ~1e16 GC/L and >70% Full Capsids at Harvest
AAVone®2.1 is designed to support the clinical and commercial scalability of AAV-based gene therapy programs. "AAV manufacturing remains one of the most important technical and economic challenges in gene therapy," said Qizhao Wang, Ph.D., Chief Technology Officer of AAVnerGene. "Conventional
More news about: AAVnerGene Inc.
May 08, 2026, 05:56 ET BioQ Debuts at in‑cosmetics Global, Showcasing China's Advancing Strength in Ingredient Innovation
skin's surface non-invasively, reaching deep into the cellular level.Through AI-guided functional programming, BEV combines an optimized ratio of gene-level active ingredients, such as miRNA, siRNA, NAD+, and PDRN, to significantly amplify its anti-aging effects. Laboratory tests show that BEV reduces
More news about: BioQ
May 08, 2026, 05:34 ET BioQ Debuts at in‑cosmetics Global, Showcasing China's Advancing Strength in Ingredient Innovation
skin's surface non-invasively, reaching deep into the cellular level.Through AI-guided functional programming, BEV combines an optimized ratio of gene-level active ingredients, such as miRNA, siRNA, NAD+, and PDRN, to significantly amplify its anti-aging effects. Laboratory
More news about: BioQ
May 08, 2026, 04:17 ET Rznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to 'RZ-001' for Hepatocellular Carcinoma
South Korea, May 8, 2026 /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based gene therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation
More news about: Rznomics
May 07, 2026, 19:18 ET LiT Biosciences, LLC Launches Patent-Pending LiT Protect, a Scientist-Founded Botanical Dietary Supplement for Everyday Wellness
systems, cytochrome P450 biology, toxicological evaluation and the biological effects of environmental mixtures.Dr. Li developed the CHO/HGPRT gene mutation assay, a widely adopted method for evaluating chemical mutagenicity. While at the Lovelace Inhalation Toxicology Research Institute in Albuquerque,
More news about: LiT Biosciences, LLC
May 07, 2026, 16:05 ET Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
HighlightsELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML).In January 2026, the Company
More news about: Enliven Therapeutics, Inc.
May 07, 2026, 16:03 ET BioLife Solutions Reports First Quarter 2026 Financial Results
Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2026.
More news about: BioLife Solutions, Inc.
May 07, 2026, 14:40 ET Franklin Biolabs and RareMoon Consulting announce a Strategic Partnership to integrate Preclinical Development with Regulatory Expertise
partner in bringing transformative cell and gene therapies to patients worldwide."Sabrina Mogle, Co‑Founder and Chief Executive Officer of RareMoon Consulting, added, "This strategic alignment with Franklin Biolabs creates a powerful opportunity for our gene therapy and rare disease clients to move
More news about: Franklin Biolabs
May 07, 2026, 10:54 ET Advaita Bio bringt iSCanGuide™ auf den Markt: Vereinheitlichte Analyse für Einzelzell-Transkriptomik und räumliche Transkriptomik, gestützt auf GPU-beschleunigte Infrastruktur
vollständiger Unterstützung für 10x Genomics Visium (Standard/HD) und Xenium. Räumliche Zellverteilungen lassen sich visualisieren und räumlich variable Gene identifizieren, und zwar innerhalb derselben Umgebung, die für Einzelzell-RNA-seq verwendet wird, ohne dass ein Datenexport erforderlich ist.Integrierte
More news about: Advaita Bio